These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3821640)

  • 1. Monobenzone, Superfade, vitiligo and confetti-like depigmentation.
    Catona A; Lanzer D
    Med J Aust; 1987 Mar; 146(6):320-1. PubMed ID: 3821640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confetti-like depigmentation from hydroquinone.
    Markey AC; Black AK; Rycroft RJ
    Contact Dermatitis; 1989 Feb; 20(2):148-9. PubMed ID: 2706964
    [No Abstract]   [Full Text] [Related]  

  • 3. Q-Switched Alexandrite Laser and Topical 20% Monobenzyl Ester of Hydroquinone Removal of Tacrolimus-Induced Repigmentation (After Complete Depigmentation With 20% Monobenzyl Ether of Hydroquinone).
    McGuinn KP; Saedi N; Green JB; Dover JS
    Dermatol Surg; 2019 May; 45(5):756-757. PubMed ID: 30893165
    [No Abstract]   [Full Text] [Related]  

  • 4. [Melanoleukoderma following treatment with hydroquinone monobenzylether].
    Balabanow K; Durmischev AL; Tschernozemsky I
    Asthet Med (Berl); 1968 Oct; 17(10):233-4. PubMed ID: 5306153
    [No Abstract]   [Full Text] [Related]  

  • 5. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone.
    Arowojolu OA; Orlow SJ; Elbuluk N; Manga P
    Exp Dermatol; 2017 Jul; 26(7):637-644. PubMed ID: 28370349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current contact news. Hydroquinone uses and abnormal reactions.
    Fisher AA
    Cutis; 1983 Mar; 31(3):240-4, 250. PubMed ID: 6220868
    [No Abstract]   [Full Text] [Related]  

  • 7. [Depigmentation effect of hydroquinone monomethyl ether].
    Durmischev AL; Davidoff MS
    Dermatol Monatsschr; 1976 Apr; 162(4):306-11. PubMed ID: 955213
    [No Abstract]   [Full Text] [Related]  

  • 8. Corneal and conjunctival effects of monobenzone in patients with vitiligo.
    Hedges TR; Kenyon KR; Hanninen LA; Mosher DB
    Arch Ophthalmol; 1983 Jan; 101(1):64-8. PubMed ID: 6849655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mouse model of vitiligo induced by monobenzone.
    Zhu Y; Wang S; Xu A
    Exp Dermatol; 2013 Jul; 22(7):499-501. PubMed ID: 23800067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid repigmentation after depigmentation therapy: vitiligo treated with monobenzyl ether of hydroquinone.
    Oakley AM
    Australas J Dermatol; 1996 May; 37(2):96-8. PubMed ID: 8687336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical monobenzyl ether of hydroquinone is an effective and safe treatment for depigmentation of extensive vitiligo in the medium term: a retrospective cohort study of 53 cases.
    Tan ES; Sarkany R
    Br J Dermatol; 2015 Jun; 172(6):1662-1664. PubMed ID: 25556887
    [No Abstract]   [Full Text] [Related]  

  • 12. [Accidental leukomelanoderma induced by topical depigmenting agents].
    Frenk E
    Ann Dermatol Venereol; 1983; 110(4):381-2. PubMed ID: 6625461
    [No Abstract]   [Full Text] [Related]  

  • 13. Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo.
    Sosa JJ; Currimbhoy SD; Ukoha U; Sirignano S; O'Leary R; Vandergriff T; Hynan LS; Pandya AG
    J Am Acad Dermatol; 2015 Aug; 73(2):272-5. PubMed ID: 26054430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical-Induced Vitiligo.
    Harris JE
    Dermatol Clin; 2017 Apr; 35(2):151-161. PubMed ID: 28317525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Leukomelanodermia areata (dyschromia "en confetti") caused by the application of monobenzylether of hydroquinone (author's transl)].
    Kastl J; Horácek J
    Cesk Dermatol; 1981 Oct; 56(5):312-7. PubMed ID: 7307092
    [No Abstract]   [Full Text] [Related]  

  • 16. Cutaneous reactions to topical application of hydroquinone. Results of a 6-year investigation.
    Bentley-Phillips B; Bayles MA
    S Afr Med J; 1975 Aug; 49(34):1391-5. PubMed ID: 1162515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Confetti-like dyschromia caused by a bleaching cream containing hydroquinone in racially pigmented patients].
    Haas N
    Med Klin (Munich); 1988 May; 83(11):385-6, 390. PubMed ID: 3405155
    [No Abstract]   [Full Text] [Related]  

  • 18. [Acquired leukomelanoderma caused by topical depigmenting agents].
    Grojean MF; Thivolet J; Perrot H
    Ann Dermatol Venereol; 1982; 109(8):641-7. PubMed ID: 7187189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depigmentation therapies for normal skin in vitiligo universalis.
    AlGhamdi KM; Kumar A
    J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):749-57. PubMed ID: 21054565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occupational depigmentation due to a hydroquinone-containing photographic developer.
    Frenk E; Loi-Zedda P
    Contact Dermatitis; 1980 Apr; 6(3):238-9. PubMed ID: 6446441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.